In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qiagen NV

www.qiagen.com

Latest From Qiagen NV

Qiagen In Crisis, Previews Poor Q3 Sales; Long-Term CEO Steps Down

Qiagen shares took a hit following a series of negative announcements, including lower than expected results for Q3 2019 and the departure of long-term CEO Peer Schatz. The company said it had been affected by poor sales growth in China.

Sales & Earnings In Vitro Diagnostics

Novartis CEO Calms Concerns Over Zolgensma launch

The Swiss major has posted a strong set of financials for the second quarter and Vas Narasimhan is pleased with the roll-out of Zolgensma, Mayzent and Piqray.

Launches Sales & Earnings

Pacts In Medtech: Cook Will Sell Ambu’s Duodenoscopes; QXMedical Gets UMinnesota’s Bioresorbable Embolic

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in May and June 2019.

Pacts in Medtech Deals

Qiagen Launches First FDA-Approved Companion Diagnostic For Novartis’ Alpelisib

The US FDA approved Qiagen’s therascreen PIK3CA RGQ PCR kit to guide treatment of breast cancer with Novartis’ new drug Piqray (alpelisib).

Approvals Innovation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register